Scalability considerations when using cord blood as an allogeneic starting material
On demand

Scalability considerations when using cord blood as an allogeneic starting material

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Scalability considerations when using cord blood as an allogeneic starting material

Once discarded as medical waste, cord blood is now recognized as a valuable source of stem cells that is simple to collect and store, rapidly available and is less likely to promote an immune response.

For nearly 30 years, physicians have used cord blood as a cell source for hematopoietic stem cell transplant (HSCT) to treat hematologic malignancies and disorders in children and adults. While cord blood has been used to provide life-saving treatments to patients for decades, its full potential has not yet been tapped.

Cell and gene therapy researchers have now also demonstrated value for the use of cord blood units (CBUs) as a source material. For example, researchers have isolated NK cells from cord blood for CAR-NK therapies as well as using cord blood for induced pluripotent stem cell generation. Using CBUs as source material for new cell and gene therapies is a fantastic use of this resource and can provide more treatment options to patients.

During this webinar we will discuss the evolution of cord blood to treat disease, the benefits of cord blood as a source material for cell and gene therapies and considerations for contracting with multiple cord blood banks

Attend this webinar to learn:

  • The importance of having a good understanding of critical starting material attributes, and how this may impact your starting material supply 
  • How and why cord blood is a valuable starting material for emerging cell therapies
  • The value of sourcing cord blood units across multiple banks to achieve supply scalability and sustainability
  • Why alignment on necessary updates to banking practices to facilitate future usage of cord blood will be required for scalable supply

Joy Aho PhD
Joy Aho PhD
Be The Match BioTherapies

Joy Aho, PhD, is the Senior Product Managerat Be The Match BioTherapies®, where she develops innovative products andbest-in-class services for the cell and gene therapy industry. Prior to joiningthe team, she worked in product development and management at Bio-Techne for 13years designing pioneering clinical and discovery tools for the development of celland gene therapies. Aho received her PhD in Molecular, Cellular, andDevelopmental Biology & Genetics from the University of Minnesota, and her researchled her to studying the role of TGFß family proteins during embryonic development utilizingstem cells and developmental models.

Wouter van’t Hof PhD
Wouter van’t Hof PhD
Cleveland Cord Blood Center

Wouter Van’t Hof holds a PhD in Cell Biology from Utrecht University in the Netherlands, and has over 15 years of biotech experience in the USA in translational research and development of adult stem cell therapies, including bone marrow stromal cells (MSC) and HPC, cord blood. He is currently Cord Blood Bank Director of the Cleveland Cord Blood Center (CCBC). Under his direction, CCBC obtained FDA approval for the manufacture and distribution of HPC, Cord Blood under federal license, as one of only eight nationally licensed cord blood banks in the USA. As Cord Blood Bank Director he oversees Laboratory Operations, including CMC, Process Validation, Aseptic Processing, and GMP compliance. In addition, Wouter leads the Cell Therapy Incubator (CTI), a new CCBC initiative facilitating internal and external programs for broader development of cord blood cell-based therapies in regenerative medicine. From 2002 to 2013, he was a Director at Athersys, Inc., with responsibility for technology transfer, product and process development, preclinical safety, and was deeply involved in regulatory discussion for clinical study design and management of a GVHD prophylaxis trial. He was the scientific lead on the completed Phase 1 safety study in HSCT support for the MultiStem Product. During his academic career, Dr Van’t Hof was an Assistant Professor of Cell Biology in Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, and Assistant Professor of Genetic Medicine, Institute of Genetic Medicine, Weill Medical College of Cornell University.

Ann Kaestner
Ann Kaestner
CCBB Associate Director at